TRDA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TRDA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Entrada Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $5.712. Entrada Therapeutics's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.
As of today (2025-04-07), Entrada Therapeutics's share price is $7.92. Entrada Therapeutics's Median PS Value is $0.00. Therefore, Entrada Therapeutics's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Entrada Therapeutics's Median PS Value or its related term are showing as below:
The historical data trend for Entrada Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entrada Therapeutics Annual Data | |||||||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Median PS Value | Get a 7-Day Free Trial | - | - | - | - | - |
Entrada Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Median PS Value | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Entrada Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Entrada Therapeutics's Price-to-Median-PS-Value falls into.
Entrada Therapeutics's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | 5.712 | * | 0 | |
= | 0.00 |
10-Year Median PS Ratio is 0.
Entrada Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.712.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entrada Therapeutics (NAS:TRDA) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Entrada Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 7.92 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Entrada Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Kory James Wentworth | officer: Chief Financial Officer | 6 TIDE STREET, C/O ENTRADA THERAPEUTICS, BOSTON MA 02210 |
Mpm Bioventures 2018, L.p. | 10 percent owner | 450 KENDALL STREET, CAMBRIDGE MA 02142 |
Mpm Bioventures 2014, L.p. | 10 percent owner | C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142 |
Natarajan Sethuraman | officer: Chief Scientific Officer | 6 TIDE STREET, BOSTON MA 02210 |
Nathan J Dowden | officer: Chief Operating Officer | 6 TIDE STREET, BOSTON MA 02210 |
Dipal Doshi | director, officer: President and CEO | C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Peter S Kim | director | ONE MERCK DRIVE, P.O. BOX 100, WHITEHOUSE STATION X1 08889 |
Nerissa Kreher | officer: Chief Medical Officer | C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139 |
Gina Chapman | director | C/O CARGO THERAPEUTICS, INC., 1900 ALAMEDA DE LAS PULGAS, SUITE 350, SAN MATEO CA 94403 |
Bernhardt G Zeiher | director | ENTRADA THERAPEUTICS, INC., 6 TIDE STREET, BOSTON MA 02210 |
Baker Bros. Advisors Lp | 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Todd Foley | director, 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116 |
Felix Baker | 10 percent owner | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
Julian Baker | 10 percent owner | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
John F Crowley | director | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
From GuruFocus
By Marketwired • 06-03-2024
By Marketwired • 11-05-2024
By GuruFocus News • 02-04-2025
By Marketwired • 02-24-2025
By GuruFocus Research • 03-27-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 05-16-2024
By GuruFocus News • 03-01-2025
By Marketwired • 05-07-2024
By GuruFocus Research • 02-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.